viagra 'serif'">The past 10 years have brought unprecedented advances in malaria research, resulting in recommendations for frontline use of artemisinin-based combination treatments (ACTs) for patients exposed to drug-resistant malaria and long-lasting insecticide treated nets (LLINs) for personal protection. Sequencing of the genomes of Plasmodium falciparum, Anopheles gambiae, and humans offers great opportunity for better understanding of genetic susceptibility to infection and illness and development of improved and new diagnostics, drugs, vaccines, and insecticides. Research coalitions supported by the United States National Institutes of Health, Welcome Trust, Bill & Melinda Gates Foundation, the Multilateral Initiative on Malaria (MIM), and the Special Programme for Research and Training at the World Health Organization (WHO) are spearheading these break troughs. The Global Fund for AIDS, Tuberculosis, and Malaria, the Global Malaria Programme and Roll Back Malaria Partnership (RBM) at WHO, the United States President’s Malaria Initiative (PMI), the Malaria Control Booster Program at the World Bank, the Bill & Melinda Gates Foundation, and other funding organizations are contributing hundreds of millions of dollars to malaria control based on the medical, public health, and economic burden of this disease. Most importantly, all endemic countries are developing and implementing malaria control policies, strategies, and plans: many countries are increasing coverage and use of drugs and nets and insecticide residual spraying (IRS) of homes is making a comeback. 

Joel G. Breman, Martin S. Alilio, and Nicholas J. White; 2007